In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novation's Debut

Executive Summary

The new merged supply chain programs of VHA and University Hospital Consortium is off the ground, headed by a former Baxter executive. The question for suppliers is the approach the organization will take--confrontational or conciliatory--as it shapes a dedicated program.

You may also be interested in...



Novation's Play in Physician-Preferred Products

The Senate hearings held last year on hospital group purchasing highlighted one of the most difficult challenges hospital groups face: getting physician-preferred products like drug-eluting stents and orthopedic implants under contract. For the past ten years, Novation has had a program focused specifically on such high tech devices, and though it hasn't always been easy, the program has been remarkably successful in getting manufacturers to put products on contract.

December ANDA Rush Is Largest In Two Years

December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.

Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM

Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.

Topics

Related Companies

UsernamePublicRestriction

Register

IV000806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel